ChiCTR2100050308 版本V1.2 版本创建时间2022/03/28 17:46:34 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100050308 

最近更新日期:

Date of Last Refreshed on:

2022-03-28 17:34:51 

注册时间:

Date of Registration:

2021-08-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

阴茎勃起硬度值对前列腺癌根治术后阴茎康复的预测作用

Public title:

Predictive effect of penile erectile hardness value on penile recovery after radical resection of prostate cancer

注册题目简写:

English Acronym:

研究课题的正式科学名称:

阴茎勃起硬度值对前列腺癌根治术后阴茎康复的预测作用

Scientific title:

Predictive effect of penile erectile hardness value on penile recovery after radical resection of prostate cancer

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

邢召全 

研究负责人:

邢召全 

Applicant:

Zhaoquan Xing 

Study leader:

Zhaoquan Xing 

申请注册联系人电话:

Applicant telephone:

18560083901

研究负责人电话:

Study leader's
telephone:

18560083901

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sdql2011@126.com

研究负责人电子邮件:

Study leader's E-mail:

sdql2011@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市文化西路107号

研究负责人通讯地址:

山东省济南市文化西路107号

Applicant address:

Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong,China

Study leader's address:

Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong,China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东大学齐鲁医院

Applicant's institution:

Qilu Hospital of Shandong University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(科)伦审第2020(061)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学齐鲁医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Qilu Hospital of Shandong University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-12-25 00:00:00

伦理委员会联系人:

傅昌

Contact Name of the ethic committee:

Chang Fu

伦理委员会联系地址:

山东省济南市文化西路107号

Contact Address of the ethic committee:

Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong,China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学齐鲁医院

Primary sponsor:

Qilu Hospital of Shandong University

研究实施负责(组长)单位地址:

山东省济南市文化西路107号

Primary sponsor's address:

Qilu Hospital of Shandong University, 107 Wenhuaxi Road, Jinan, Shandong,China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学齐鲁医院

具体地址:

历下区文化西路107号

Institution
hospital:

Qilu Hospital of Shandong University

Address:

107 Wenhua Road West, Lixia District

经费或物资来源:

山东大学临床研究项目

Source(s) of funding:

Clinical Research project of Shandong University

研究疾病:

前列腺癌  

Target disease:

Prostate cancer

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

建立具有预测价值的术前夜间勃起监测(NPTR)基础硬度值联合其他临床指标的前列腺癌根治术(RP)患者术后6个月勃起功能障碍的精准预测模型。  

Objectives of Study:

To establish an accurate predictive model of erectile dysfunction 6 months after radical prostate cancer surgery (RP) based on preoperative nocturnal erectile monitoring (NPTR) basic hardness value combined with other clinical indicators.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①患者年龄在70岁以下,签署知情同意;②研究对象为经临床病理确诊为前列腺癌的患者,参照美国抗癌协会(AJCC)2002年的标准,并接受标准的Walsh双侧神经保留手术,所使用的麻醉药物、方式、时间等均固定;③术者固定为有经验的专科医生(手术例数>300台),手术方式为固定术式,手术时间控制在2小时以内,手术地点固定,出血量<50ml,不损伤其他器官组织;④同意接受RP术后阴茎康复治疗,服用药物剂量及时间固定;⑤术后无严重并发症和/或其他重大慢性疾病。

Inclusion criteria

① The patient is under the age of 70 years old and signed the informed consent;② The subjects were patients with clinically pathologically diagnosed prostate cancer, who received standard Walsh bilateral nerve spreservation surgery according to the standards of the American Anti-Cancer Society (AJCC) in 2002, and the anesthetic drugs, methods and time were fixed;③ The surgeons were fixed as experienced specialists (the number of surgical cases was > 300), the operation method was fixed operation, the operation time was controlled within 2 hours, the operation site was fixed, and the amount of blood loss was <50ml, no damage to other organs and tissues;(4) agree to receive penile rehabilitation treatment after RP operation, and take drug dosage and time fixed;⑤ No serious complications and/or other major chronic diseases were found after surgery.

排除标准:

①年龄>70岁,或者未签署知情同意;②术中未行双侧神经保留术;③术后严重并发症,如尿失禁、严重血尿、感染;④术后短期内肿瘤复发转移;⑤无性生活需求或不接受术后阴茎康复治疗无糖尿病、严重肥胖、脂肪肝、痛风以及伴有其他严重疾病如恶性肿瘤、慢性肝肾疾病等;⑥合并慢性疾病,如糖尿病、其他恶性肿瘤、肝肾功能不全及严重心血管疾病等。

Exclusion criteria:

(1) The patient is more than 70 years old, or have not signed the informed consent;② Bilateral nerve sparing was not performed intraoperatively;③ Serious postoperative complications, such as urinary incontinence, severe hematuria, infection;(4) Tumor recurrence and metastasis in a short period after surgery;(5) No need for sexual life or no postoperative penile rehabilitation treatment; no diabetes, severe obesity, fatty liver, gout, or other serious diseases such as malignant tumor, chronic liver and kidney disease;(6) Complicated with chronic diseases, such as diabetes, other malignant tumors, liver and kidney insufficiency and serious cardiovascular diseases.

研究实施时间:

Study execute time:

From 2021-09-01 00:00:00 To 2023-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-09-01 00:00:00 To 2022-12-31 00:00:00

干预措施:

Interventions:

组别:

ED组

样本量:

52

Group:

ED group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

正常组

样本量:

52

Group:

Normal group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学齐鲁医院 

单位级别:

三级甲等 

Institution
hospital:

Qilu Hospital of Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

夜间阴茎胀大硬度测定

指标类型:

主要指标

Outcome:

Determination of nocturnal penile dilation hardness

Type:

Primary indicator

测量时间点:

测量方法:

国际勃起功能评分表

Measure time point of outcome:

Measure method:

International Erectile Function Scale

指标中文名:

勃起硬度评分

指标类型:

主要指标

Outcome:

Erectile hardness score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

收集来源山东大学齐鲁医院泌尿外科2021年1月-2022年6月连续入组的前列腺癌住院手术患者,开展前瞻性队列研究和巢式病例对照研究。

Randomization Procedure (please state who generates the random number sequence and by what method):

a prospective cohort study and a nested case-control study were conducted among consecutive patients with prostate cancer from January 2021 to June 2022 in the Department of Urology, Qilu Hospital, Shandong University

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023年公布,采用第三方网络平台

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Announced in 2023, the third-party network platform is adopted

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-08-26 11:02:34